Moderna announced the departure of Chief Medical Officer Jacqueline Miller after roughly a year in the role and concurrently out‑licensed a Phase‑3 rare‑disease asset to Recordati for $50 million upfront. The licensing deal transfers late‑stage responsibility for the candidate and provides Moderna immediate non‑dilutive capital. The personnel change comes amid broader R&D realignment as Moderna balances mRNA platform investments with rare‑disease and commercial priorities. Recordati will take on registrational execution while Moderna retains program‑level economics as defined in the licensing terms.